Transcatheter Aortic Valve Replacement (TAVR)
15
6
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
20%
3 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (15)
Patient Quality of Recovery After TAVR With Different Sedation Regimens
EasyCrossTM Device-Self-centering Catheter
RAFT-TAVR PACE: LBBAP vs. RVP Post-TAVR in Patients Requiring PPI
Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve
Frequency of Electrical Acupoint Stimulation on Hypotension in TAVR Patients
TAVR for Aortic Regurgitation Under TTE Guidance
Phenotyping Left Ventricle Failure With Hemodynamic Biomarkers From 4D Flow Magnetic Resonance Imaging
TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System
CardioLogical Interventions and Acute strOke Treatment sTudy
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
Outcomes for Patients With Ascending Aortic Dilation Who Underwent TAVR
Assessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial
A Clinical Study on the Use of the Sentinel Cerebral Protection Device During TAVR for the Prevention of Procedure-Related Stroke
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
Transcatheter Aortic Valve Replacement (TAVR)-Pilot Trial